1
|
Piniella D, Zafra F. Functional crosstalk of the glycine transporter GlyT1 and NMDA receptors. Neuropharmacology 2023; 232:109514. [PMID: 37003571 DOI: 10.1016/j.neuropharm.2023.109514] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2022] [Revised: 03/10/2023] [Accepted: 03/20/2023] [Indexed: 04/03/2023]
Abstract
NMDA-type glutamate receptors (NMDARs) constitute one of the main glutamate (Glu) targets in the central nervous system and are involved in synaptic plasticity, which is the molecular substrate of learning and memory. Hypofunction of NMDARs has been associated with schizophrenia, while overstimulation causes neuronal death in neurodegenerative diseases or in stroke. The function of NMDARs requires coincidental binding of Glu along with other cellular signals such as neuronal depolarization, and the presence of other endogenous ligands that modulate their activity by allosterism. Among these allosteric modulators are zinc, protons and Gly, which is an obligatory co-agonist. These characteristics differentiate NMDARs from other receptors, and their structural bases have begun to be established in recent years. In this review we focus on the crosstalk between Glu and glycine (Gly), whose concentration in the NMDAR microenvironment is maintained by various Gly transporters that remove or release it into the medium in a regulated manner. The GlyT1 transporter is particularly involved in this task, and has become a target of great interest for the treatment of schizophrenia since its inhibition leads to an increase in synaptic Gly levels that enhances the activity of NMDARs. However, the only drug that has completed phase III clinical trials did not yield the expected results. Notwithstanding, there are additional drugs that continue to be investigated, and it is hoped that knowledge gained from the recently published 3D structure of GlyT1 may allow the rational design of more effective new drugs.
Collapse
Affiliation(s)
- Dolores Piniella
- Centro de Biología Molecular Severo Ochoa, Facultad de Ciencias, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Madrid, Spain; IdiPAZ, Institute of Health Carlos III (ISCIII), Spain
| | - Francisco Zafra
- Centro de Biología Molecular Severo Ochoa, Facultad de Ciencias, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Madrid, Spain; IdiPAZ, Institute of Health Carlos III (ISCIII), Spain.
| |
Collapse
|
2
|
Lee BJ, Ickes AR, Gupta AK, Ensign SC, Ho TD, Tarasewicz A, Vanable EP, Kortman GD, Hull KL. Synthesis of Unsymmetrical Vicinal Diamines via Directed Hydroamination. Org Lett 2022; 24:5513-5518. [PMID: 35862860 DOI: 10.1021/acs.orglett.2c01911] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Vicinal diamines are a common motif found in biologically active molecules. The hydroamination of allyl amine derivatives is a powerful approach for the synthesis of substituted 1,2-diamines. Herein, the rhodium-catalyzed hydroamination of primary and secondary allylic amines using diverse amine nucleophiles, including primary, secondary, acyclic, and cyclic aliphatic amines to access a wide range of unsymmetrical vicinal diamines, is presented. The utility of this methodology is further demonstrated through the rapid synthesis of several bioactive molecules and analogs.
Collapse
Affiliation(s)
- Byung Joo Lee
- Department of Chemistry, University of Texas at Austin, 105 E 24th St., Austin, Texas 78712, United States
| | - Andrew R Ickes
- Department of Chemistry, University of Illinois Urbana-Champaign, 600 S. Mathews, Urbana, Illinois 61812, United States
| | - Anil K Gupta
- Department of Chemistry, University of Illinois Urbana-Champaign, 600 S. Mathews, Urbana, Illinois 61812, United States
| | - Seth C Ensign
- Department of Chemistry, University of Illinois Urbana-Champaign, 600 S. Mathews, Urbana, Illinois 61812, United States
| | - Tam D Ho
- Department of Chemistry, University of Texas at Austin, 105 E 24th St., Austin, Texas 78712, United States
| | - Anika Tarasewicz
- Department of Chemistry, University of Texas at Austin, 105 E 24th St., Austin, Texas 78712, United States
| | - Evan P Vanable
- Department of Chemistry and Biochemistry, Elmhust University, 190 Prospect Avenue, Elmhurst, Illinois 60126, United States
| | - Gregory D Kortman
- Department of Chemistry, University of Texas at Austin, 105 E 24th St., Austin, Texas 78712, United States
| | - Kami L Hull
- Department of Chemistry, University of Texas at Austin, 105 E 24th St., Austin, Texas 78712, United States.,Department of Chemistry, University of Illinois Urbana-Champaign, 600 S. Mathews, Urbana, Illinois 61812, United States
| |
Collapse
|
3
|
Harhai M, Harsing, Jr LG. An Overview of Glycine Transporter Subtype 1 Inhibitors Under Preclinical and Clinical Evaluation for the Treatment of Alcohol Abuse. CURRENT PSYCHIATRY RESEARCH AND REVIEWS 2022. [DOI: 10.2174/2666082218666220126111415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Abstract:
Being a historical issue that withstands multiple societal control measures, alcohol abuse remains a major healthcare problem. Despite worldwide efforts to limit consumption and educate people about its effects, consumption rates remain unchanged. Alcohol abuse arises from chronic alcohol exposure-caused permanent synaptic plasticity changes in the brain. These manifest in life-threatening withdrawal symptoms and drive relapse even after detoxification and treatment. Since ethanol has multiple targets in the human brain, it warrants a multiapproach therapy; here we introduce the potential therapeutic effects of glycine transporter subtype 1 inhibitors. We have listed the various glycine transporter 1 inhibitors used in studies of alcoholism and how they influenced glycine release from rat hippocampus was demonstrated in a preliminary study. Glycine transporters modulate both glutamatergic and glycinergic pathways: (i) glutamatergic neurotransmission plays an important role in the development of chronic changes in alcoholism as daily alcohol administration was shown to increase N-methyl-D-aspartic acid receptor activity long-term, and (ii) ethanol has access to the dopaminergic reward system via glycine receptors, being an allosteric modulator of glycine receptors. This manuscript summarises the progress and development of glycine transporter 1 inhibitors, characterizing them by their mode of action, adverse effects, and discusses their clinical applicability. Furthermore, we highlight the progress in the latest clinical trials, outline currently applied treatment methods, and offer suggestions for implementing glycine transporter 1 inhibitors into the long-term treatment of alcohol abuse.
Collapse
Affiliation(s)
- Marcell Harhai
- Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary
| | - Laszlo G. Harsing, Jr
- Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary
| |
Collapse
|
4
|
Pei JC, Luo DZ, Gau SS, Chang CY, Lai WS. Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia. Front Psychiatry 2021; 12:742058. [PMID: 34658976 PMCID: PMC8517243 DOI: 10.3389/fpsyt.2021.742058] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Accepted: 09/02/2021] [Indexed: 12/30/2022] Open
Abstract
Schizophrenia is a severe mental illness that affects ~1% of the world's population. It is clinically characterized by positive, negative, and cognitive symptoms. Currently available antipsychotic medications are relatively ineffective in improving negative and cognitive deficits, which are related to a patient's functional outcomes and quality of life. Negative symptoms and cognitive deficits are unmet by the antipsychotic medications developed to date. In recent decades, compelling animal and clinical studies have supported the NMDA receptor (NMDAR) hypofunction hypothesis of schizophrenia and have suggested some promising therapeutic agents. Notably, several NMDAR-enhancing agents, especially those that function through the glycine modulatory site (GMS) of NMDAR, cause significant reduction in psychotic and cognitive symptoms in patients with schizophrenia. Given that the NMDAR-mediated signaling pathway has been implicated in cognitive/social functions and that GMS is a potential therapeutic target for enhancing the activation of NMDARs, there is great interest in investigating the effects of direct and indirect GMS modulators and their therapeutic potential. In this review, we focus on describing preclinical and clinical studies of direct and indirect GMS modulators in the treatment of schizophrenia, including glycine, D-cycloserine, D-serine, glycine transporter 1 (GlyT1) inhibitors, and D-amino acid oxidase (DAO or DAAO) inhibitors. We highlight some of the most promising recently developed pharmacological compounds designed to either directly or indirectly target GMS and thus augment NMDAR function to treat the cognitive and negative symptoms of schizophrenia. Overall, the current findings suggest that indirectly targeting of GMS appears to be more beneficial and leads to less adverse effects than direct targeting of GMS to modulate NMDAR functions. Indirect GMS modulators, especially GlyT1 inhibitors and DAO inhibitors, open new avenues for the treatment of unmet medical needs for patients with schizophrenia.
Collapse
Affiliation(s)
- Ju-Chun Pei
- Department of Psychology, National Taiwan University, Taipei, Taiwan
| | - Da-Zhong Luo
- Department of Psychology, National Taiwan University, Taipei, Taiwan
| | - Shiang-Shin Gau
- Department of Psychology, National Taiwan University, Taipei, Taiwan
| | - Chia-Yuan Chang
- Department of Psychology, National Taiwan University, Taipei, Taiwan.,Neurobiology and Cognitive Science Center, National Taiwan University, Taipei, Taiwan
| | - Wen-Sung Lai
- Department of Psychology, National Taiwan University, Taipei, Taiwan.,Neurobiology and Cognitive Science Center, National Taiwan University, Taipei, Taiwan.,Graduate Institute of Brain and Mind Sciences, National Taiwan University, Taipei, Taiwan
| |
Collapse
|
5
|
Hudson AR, Santora VJ, Petroski RE, Almos TA, Anderson G, Barido R, Basinger J, Bellows CL, Bookser BC, Broadbent NJ, Cabebe C, Chai CK, Chen M, Chow S, Chung DM, Heger L, Danks AM, Freestone GC, Gitnick D, Gupta V, Hoffmaster C, Kaplan AP, Kennedy MR, Lee D, Limberis J, Ly K, Mak CC, Masatsugu B, Morse AC, Na J, Neul D, Nikpur J, Renick J, Sebring K, Sevidal S, Tabatabaei A, Wen J, Xia S, Yan Y, Yoder ZW, Zook D, Peters M, Breitenbucher JG. Azetidine-based selective glycine transporter-1 (GlyT1) inhibitors with memory enhancing properties. Bioorg Med Chem Lett 2020; 30:127214. [PMID: 32527538 DOI: 10.1016/j.bmcl.2020.127214] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Revised: 04/22/2020] [Accepted: 04/23/2020] [Indexed: 11/24/2022]
Abstract
A strategy to conformationally restrain a series of GlyT1 inhibitors identified potent analogs that exhibited slowly interconverting rotational isomers. Further studies to address this concern led to a series of azetidine-based inhibitors. Compound 26 was able to elevate CSF glycine levels in vivo and demonstrated potency comparable to Bitopertin in an in vivo rat receptor occupancy study. Compound 26 was subsequently shown to enhance memory in a Novel Object Recognition (NOR) behavioral study after a single dose of 0.03 mg/kg, and in a contextual fear conditioning (cFC) study after four QD doses of 0.01-0.03 mg/kg.
Collapse
Affiliation(s)
- Andrew R Hudson
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States.
| | - Vincent J Santora
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Robert E Petroski
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Theresa A Almos
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Gary Anderson
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Richard Barido
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Jillian Basinger
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Chris L Bellows
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Brett C Bookser
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Nicola J Broadbent
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Clifford Cabebe
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Chih-Kun Chai
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Mi Chen
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Stephine Chow
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - De Michael Chung
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Lindsay Heger
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Anne M Danks
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Graeme C Freestone
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Dany Gitnick
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Varsha Gupta
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | | | - Alan P Kaplan
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Michael R Kennedy
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Dong Lee
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - James Limberis
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Kiev Ly
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Chi Ching Mak
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Brittany Masatsugu
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Andrew C Morse
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Jim Na
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - David Neul
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - John Nikpur
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Joel Renick
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Kristen Sebring
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Samantha Sevidal
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Ali Tabatabaei
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Jenny Wen
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Shouzhen Xia
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Yingzhuo Yan
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Zachary W Yoder
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Douglas Zook
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - Marco Peters
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| | - J Guy Breitenbucher
- Dart Neuroscience, 12278 Scripps Summit Dr, San Diego, CA 92131, United States
| |
Collapse
|
6
|
Moschetti V, Desch M, Goetz S, Liesenfeld KH, Rosenbrock H, Kammerer KP, Wunderlich G, Wind S. Safety, Tolerability and Pharmacokinetics of Oral BI 425809, a Glycine Transporter 1 Inhibitor, in Healthy Male Volunteers: A Partially Randomised, Single-Blind, Placebo-Controlled, First-in-Human Study. Eur J Drug Metab Pharmacokinet 2018; 43:239-249. [PMID: 29076028 PMCID: PMC5854750 DOI: 10.1007/s13318-017-0440-z] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
BACKGROUND AND OBJECTIVES Schizophrenia and Alzheimer's disease are characterised by glutamatergic pathway abnormalities related to N-methyl-D-aspartate (NMDA) receptor hypofunction and cognitive impairment. Glycine is an NMDA receptor co-agonist; inhibition of glycine transporter 1 (GlyT1) should improve NMDA receptor hypofunction. This study evaluated safety and pharmacokinetic properties of BI 425809-a potent and selective GlyT1 inhibitor. METHODS In the single-rising dose (SRD) component of this study, subjects were randomised to a single dose of BI 425809 [doses (mg): 0.5, 1, 2, 5, 10, 25, 50, 100 and 150], or placebo. The bioavailability/food effect (BA/FE) component investigated BI 425809 pharmacokinetics following single dosing (25-mg tablet) after overnight fasting or with a high-calorie meal or as solution (25 mg) after overnight fasting. RESULTS Overall, 33/83 (39.8%) subjects had ≥ 1 treatment-related adverse event (AE); there were no deaths or serious AEs. Reported SRD part AEs trended towards dose dependency, occurring at the higher doses (mostly central nervous system related). BI 425809 plasma concentration-time profiles were similarly shaped across all doses and plasma exposure increased proportional to dose. In the BA/FE component, geometric mean ratios for the area under the concentration-time curve from time zero to the last measurable concentration and the maximum plasma concentration for tablet fasted versus solution fasted were 80.5 and 50.0%, respectively, and for tablet fed versus fasted were 125.9 and 142.1%, respectively. CONCLUSION BI 425809 was generally well-tolerated at doses expected to be clinically relevant. The AE profile suggested possible GlyT1-inhibiting effects. CLINICAL TRIAL IDENTIFIER NCT02068690.
Collapse
Affiliation(s)
| | - Michael Desch
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
| | - Sophia Goetz
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
| | | | - Holger Rosenbrock
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
| | | | | | - Sven Wind
- Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany
| |
Collapse
|
7
|
Santora VJ, Almos TA, Barido R, Basinger J, Bellows CL, Bookser BC, Breitenbucher JG, Broadbent NJ, Cabebe C, Chai CK, Chen M, Chow S, Chung DM, Crickard L, Danks AM, Freestone GC, Gitnick D, Gupta V, Hoffmaster C, Hudson AR, Kaplan AP, Kennedy MR, Lee D, Limberis J, Ly K, Mak CC, Masatsugu B, Morse AC, Na J, Neul D, Nikpur J, Peters M, Petroski RE, Renick J, Sebring K, Sevidal S, Tabatabaei A, Wen J, Yan Y, Yoder ZW, Zook D. Design and Synthesis of Novel and Selective Glycine Transporter-1 (GlyT1) Inhibitors with Memory Enhancing Properties. J Med Chem 2018; 61:6018-6033. [DOI: 10.1021/acs.jmedchem.8b00372] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Affiliation(s)
- Vincent J. Santora
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Theresa A. Almos
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Richard Barido
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Jillian Basinger
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Chris L. Bellows
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Brett C. Bookser
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - J. Guy Breitenbucher
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Nicola J. Broadbent
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Clifford Cabebe
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Chih-Kun Chai
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Mi Chen
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Stephine Chow
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - De Michael Chung
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Lindsay Crickard
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Anne M. Danks
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Graeme C. Freestone
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Dany Gitnick
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Varsha Gupta
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Christine Hoffmaster
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Andrew R. Hudson
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Alan P. Kaplan
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Michael R. Kennedy
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Dong Lee
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - James Limberis
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Kiev Ly
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Chi Ching Mak
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Brittany Masatsugu
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Andrew C. Morse
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Jim Na
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - David Neul
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - John Nikpur
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Marco Peters
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Robert E. Petroski
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Joel Renick
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Kristen Sebring
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Samantha Sevidal
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Ali Tabatabaei
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Jenny Wen
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Yingzhuo Yan
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Zachary W. Yoder
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| | - Douglas Zook
- Dart NeuroScience LLC, 12278 Scripps Summit Drive, San Diego, California 92121, United States
| |
Collapse
|
8
|
Affiliation(s)
- Christopher L. Cioffi
- Departments of Basic and Clinical Sciences and Pharmaceutical Sciences, Albany College of Pharmacy and Health Sciences , Albany, NY, USA
| |
Collapse
|
9
|
Schmidt RW, Thompson ML. Glycinergic signaling in the human nervous system: An overview of therapeutic drug targets and clinical effects. Ment Health Clin 2016; 6:266-276. [PMID: 29955481 PMCID: PMC6007534 DOI: 10.9740/mhc.2016.11.266] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Glycine and related endogenous compounds (d-serine, d-alanine, sarcosine) serve critical roles in both excitatory and inhibitory neurotransmission and are influenced by a multitude of enzymes and transporters, including glycine transporter 1 and 2 (GlyT1 and GlyT2), d-amino acid oxidase (DAAO), serine racemase (SRR), alanine-serine-cysteine transporter 1 (Asc-1), and kynurenine aminotransferase (KAT). MEDLINE, Web of Science, and PsychINFO were searched for relevant human trials of compounds. Many studies utilizing exogenous administration of small molecule agonists of the glycineB site of n-methyl-d-aspartate receptor have been studied as have a growing number of glycine transporter type 1 (GlyT1) inhibitors. The clinical effects of these compounds are reviewed as are the potential effects of newer novel compounds.
Collapse
Affiliation(s)
- Robert W Schmidt
- Clinical Pharmacy Specialist, Mental Health, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia,
| | | |
Collapse
|
10
|
Liu Y, Guo L, Duan H, Zhang L, Jiang N, Zhen X, Shen J. Discovery of 4-benzoylpiperidine and 3-(piperidin-4-yl)benzo[d]isoxazole derivatives as potential and selective GlyT1 inhibitors. RSC Adv 2015. [DOI: 10.1039/c5ra04714e] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Two series of potential and selective GlyT1 inhibitors were discovered by bioisosteric replacement.23qwas effective on chronic PCP-treated schizophrenia-like behavioral models.
Collapse
Affiliation(s)
- Yang Liu
- State Key Laboratory of Drug Research
- Shanghai Institute of Materia Medica
- Chinese Academy of Sciences
- Shanghai 201203
- China
| | - Lin Guo
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases and Department of Pharmacology
- Soochow University
- Suzhou 215006
- China
| | - Hongliang Duan
- State Key Laboratory of Drug Research
- Shanghai Institute of Materia Medica
- Chinese Academy of Sciences
- Shanghai 201203
- China
| | - Liming Zhang
- State Key Laboratory of Drug Research
- Shanghai Institute of Materia Medica
- Chinese Academy of Sciences
- Shanghai 201203
- China
| | - Neng Jiang
- China Pharmaceutical University
- Nanjing 210009
- China
| | - Xuechu Zhen
- Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psycho-Diseases and Department of Pharmacology
- Soochow University
- Suzhou 215006
- China
| | - Jianhua Shen
- State Key Laboratory of Drug Research
- Shanghai Institute of Materia Medica
- Chinese Academy of Sciences
- Shanghai 201203
- China
| |
Collapse
|
11
|
Sy SKB, Wang X, Derendorf H. Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics. ACTA ACUST UNITED AC 2014. [DOI: 10.1007/978-1-4939-1304-6_1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
|
12
|
Spiros A, Roberts P, Geerts H. A computer-based quantitative systems pharmacology model of negative symptoms in schizophrenia: exploring glycine modulation of excitation-inhibition balance. Front Pharmacol 2014; 5:229. [PMID: 25374541 PMCID: PMC4204440 DOI: 10.3389/fphar.2014.00229] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2014] [Accepted: 09/23/2014] [Indexed: 02/04/2023] Open
Abstract
Although many antipsychotics can reasonably control positive symptoms in schizophrenia, patients' return to society is often hindered by negative symptoms and cognitive deficits. As an alternative to animal rodent models that are often not very predictive for the clinical situation, we developed a new computer-based mechanistic modeling approach. This Quantitative Systems Pharmacology approach combines preclinical basic neurophysiology of a biophysically realistic neuronal ventromedial cortical-ventral striatal network identified from human imaging studies that are associated with negative symptoms. Calibration of a few biological coupling parameters using a retrospective clinical database of 34 drug-dose combinations resulted in correlation coefficients greater than 0.60, while a robust quantitative prediction of a number of independent trials was observed. We then simulated the effect of glycine modulation on the anticipated clinical outcomes. The quantitative biochemistry of glycine interaction with the different NMDA-NR2 subunits, neurodevelopmental trajectory of the NMDA-NR2B in the human schizophrenia pathology, their specific localization on excitatory vs. inhibitory interneurons and the electrogenic nature of the glycine transporter resulted in an inverse U-shape dose-response with an optimum in the low micromolar glycine concentration. Quantitative systems pharmacology based computer modeling of complex humanized brain circuits is a powerful alternative approach to explain the non-monotonic dose-response observed in past clinical trial outcomes with sarcosine, D-cycloserine, glycine, or D-serine or with glycine transporter inhibitors. In general it can be helpful to better understand the human neurophysiology of negative symptoms, especially with targets that show non-monotonic dose-responses.
Collapse
Affiliation(s)
- Athan Spiros
- Computational Neuropharmacology, In Silico Biosciences, Inc. Berwyn, PA, USA
| | - Patrick Roberts
- Computational Neuropharmacology, In Silico Biosciences, Inc. Berwyn, PA, USA ; Department of Biomedical Engineering, Oregon Health and Science University Portland, OR, USA
| | - Hugo Geerts
- Computational Neuropharmacology, In Silico Biosciences, Inc. Berwyn, PA, USA ; Department of Laboratory Pathology, Perelman School of Medicine, University of Pennsylvania Philadelphia, PA, USA
| |
Collapse
|
13
|
O'Connor-Semmes RL, Lin J, Hodge RJ, Andrews S, Chism J, Choudhury A, Nunez DJ. GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety. Clin Pharmacol Ther 2014; 96:704-12. [PMID: 25238251 DOI: 10.1038/clpt.2014.187] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2014] [Accepted: 08/29/2014] [Indexed: 11/10/2022]
Abstract
GSK2374697 is a genetically engineered fusion protein of a human domain antibody to exendin-4. This molecule binds with a high affinity to human serum albumin, creating a long-duration glucagon-like peptide-1 (GLP-1) receptor agonist. This study is the first evaluation of the albumin-binding domain antibody (AlbudAb) drug delivery platform in humans. The aim of this randomized clinical study was to determine the pharmacokinetics, pharmacodynamics, safety, and tolerability of GSK2374697. The pharmacokinetic profile was prolonged, with estimated half-lives ranging from 6 to 10 days. Postprandial glucose and insulin were reduced, and gastric emptying was delayed in healthy subjects, confirming anticipated GLP-1 receptor agonist pharmacology. The safety and tolerability were as expected for a potent GLP-1 agonist. Gradual titration of doses greatly improved tolerability. Rapid tolerance to nausea was observed. Study results support further investigation in type 2 diabetes and for weight loss.
Collapse
Affiliation(s)
| | - J Lin
- GlaxoSmithKline, R&D, Research Triangle Park, North Carolina, USA
| | - R J Hodge
- GlaxoSmithKline, R&D, Research Triangle Park, North Carolina, USA
| | - S Andrews
- GlaxoSmithKline, R&D, Research Triangle Park, North Carolina, USA
| | - J Chism
- GlaxoSmithKline, R&D, Research Triangle Park, North Carolina, USA
| | - A Choudhury
- GlaxoSmithKline, R&D, King of Prussia, Pennsylvania, USA
| | - D J Nunez
- GlaxoSmithKline, R&D, Research Triangle Park, North Carolina, USA
| |
Collapse
|
14
|
Liem-Moolenaar M, Peeters P, Kamerling IMC, Hogg C, Holder G, Kleijn HJ, Spaans E, Udo De Haes J, de Kam ML, Franson KL, Cohen AF, van Gerven JMA. Early stage development of the glycine-1 re-uptake inhibitor SCH 900435: central nervous system effects compared with placebo in healthy men. Br J Clin Pharmacol 2014; 75:1455-67. [PMID: 23116363 DOI: 10.1111/bcp.12015] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2011] [Accepted: 10/07/2012] [Indexed: 01/05/2023] Open
Abstract
AIMS To report the first three studies with SCH 900435, a selective glycine-1 re-uptake inhibitor in development for treating schizophrenia, using systematic evaluations of pharmacodynamics to understand the observed effects. METHODS Three double-blind, placebo-controlled studies (single, visual effect and multiple dose) were performed. In the single and multiple dose study SCH 900435 (0.5-30 mg) was given to healthy males and frequent pharmacokinetic and pharmacodynamic measurements were performed. The visual effects study incorporated visual electrophysiological measures of macular, retinal and intracranial visual pathway function. RESULTS In the single dose study (highest difference, 95% CI, P) increases in smooth pursuit eye movements (8, 12 mg (-6.09, 10.14, -2.04, 0.013), 30 mg), pupil : iris ratio (20 and 30 mg (-0.065, 0.09, -0.04, <0.0001)), VAS colour perception (30 mg (-9.48, 13.05, -5.91, <0.0001)) and changes in spontaneous reports of visual disturbance were found, while FSH (8 mg (0.42, 0.18, 0.66, 0.0015), 12, 20 mg), LH (8-30 mg (1.35, 0.65, 2.05, 0.0003)) and EEG alpha2 activity decreased (12, 20, 30 mg (0.27, 0.14, 0.41, 0.0002)). A subsequent dedicated visual effects study demonstrated that visual effects were transient without underlying electrophysiological changes. This provided enough safety information for starting a multiple ascending dose study, showing less visual symptoms after twice daily dosing and titration, possibly due to tolerance. CONCLUSIONS Several central nervous system (CNS) effects and gonadotropic changes resulted from administration of 8 mg and higher, providing evidence for CNS penetration and pharmacological activity of SCH 900435. Antipsychotic activity in patients, specificity of the reported effects for this drug class and possible tolerance to visual symptoms remain to be established.
Collapse
|
15
|
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain. Nat Rev Drug Discov 2014; 12:866-85. [PMID: 24172334 DOI: 10.1038/nrd3893] [Citation(s) in RCA: 154] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Glycine transporters are endogenous regulators of the dual functions of glycine, which acts as a classical inhibitory neurotransmitter at glycinergic synapses and as a modulator of neuronal excitation mediated by NMDA (N-methyl-D-aspartate) receptors at glutamatergic synapses. The two major subtypes of glycine transporters, GlyT1 and GlyT2, have been linked to the pathogenesis and/or treatment of central and peripheral nervous system disorders, including schizophrenia and related affective and cognitive disturbances, alcohol dependence, pain, epilepsy, breathing disorders and startle disease (also known as hyperekplexia). This Review examines the rationale for the therapeutic potential of GlyT1 and GlyT2 inhibition, and surveys the latest advances in the biology of glycine reuptake and transport as well as the drug discovery and clinical development of compounds that block glycine transporters.
Collapse
|
16
|
GlyT-1 Inhibitors: From Hits to Clinical Candidates. SMALL MOLECULE THERAPEUTICS FOR SCHIZOPHRENIA 2014. [DOI: 10.1007/7355_2014_53] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
17
|
Liu CN, Pettersen B, Seitis G, Osgood S, Somps C. GlyT1 inhibitor reduces oscillatory potentials of the electroretinogram in rats. Cutan Ocul Toxicol 2013; 33:206-11. [DOI: 10.3109/15569527.2013.833937] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
18
|
Sy SKB, Heuberger J, Shilbayeh S, Conrado DJ, Derendorf H. A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation. AAPS JOURNAL 2013; 15:1189-99. [PMID: 23990505 DOI: 10.1208/s12248-013-9528-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2013] [Accepted: 08/12/2013] [Indexed: 12/19/2022]
Abstract
The SNP A6986G of the CYP3A5 gene (*3) results in a non-functional protein due to a splicing defect whereas the C3435T was associated with variable expression of the ABCB1 gene, due to protein instability. Part of the large interindividual variability in tacrolimus efficacy and toxicity can be accounted for by these genetic factors. Seventy-two individuals were examined for A6986G and C3435T polymorphism using a PCR-RFLP-based technique to estimate genotype and allele frequencies in the Jordanian population. The association of age, hematocrit, platelet count, CYP3A5, and ABCB1 polymorphisms with tacrolimus dose- and body-weight-normalized levels in the subset of 38 pediatric renal transplant patients was evaluated. A Markov model was used to evaluate the time-dependent probability of an adverse event occurrence by CYP3A5 phenotypes and ABCB1 genotypes. The time-dependent probability of adverse event was about double in CYP3A5 non-expressors compared to the expressors for the first 12 months of therapy. The CYP3A5 non-expressors had higher corresponding normalized tacrolimus levels compared to the expressors in the first 3 months. The correlation trend between probability of adverse events and normalized tacrolimus concentrations for the two CYP3A5 phenotypes persisted for the first 9 months of therapy. The differences among ABCB1 genotypes in terms of adverse events and normalized tacrolimus levels were only observed in the first 3 months of therapy. The information on CYP3A5 genotypes and tacrolimus dose requirement is important in designing effective programs toward management of tacrolimus side effects particularly for the initial dose when tacrolimus blood levels are not available for therapeutic drug monitoring.
Collapse
Affiliation(s)
- Sherwin K B Sy
- Department of Pharmaceutics, College of Pharmacy, University of Florida, P.O. Box 100494, 1600 Archer Road, Gainesville, Florida, 32610, USA
| | | | | | | | | |
Collapse
|